Generate Biomedicines Expands Leadership Team with Chief Digital Officer

Generate Biomedicines announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer. He will lead multidisciplinary teams across technology, data science, automation, and digital transformation to support the rapid growth of the machine learning-powered biotech.

Recommended AI News: A Bad Customer Experience Is Worse Than Shipment Delays, Say 76% Of Americans

“I’m thrilled and honored to be part of this supremely talented team that combines generative AI with leading-edge automation and wet-lab science to reprogram human biology and transform the discovery and development of protein therapeutics at a speed and scale never seen before in our industry.”

Dr. Agrafiotis brings deep expertise at the intersection of digital technology, data science, and life sciences spanning the entire R&D continuum across venture-funded biotech, big pharma, and the services industry. He was Vice President at Pfizer Digital, where he was responsible for the digital strategy and portfolio for Pfizer’s Worldwide Research, Development and Medical organization. Prior to that, he served as Chief Information Officer of the Novartis Institutes for Biomedical Research leading Novartis’ global digital and informatics organization for its research and early development division.

“We’re delighted and proud to welcome Dimitris to the Generate team to help us expand and scale our technology and generative biology platform as we enter this exciting new phase in the company’s evolution,” said Mike Nally, Chief Executive Officer of Generate Biomedicines. “Dimitris’ unique blend of digital, data, and life science experience and impressive record of innovation will help us revolutionize drug discovery and development and create life-saving treatments for some of the world’s most pressing medical needs.”

Recommended AI News: Blackline Safety Acquires IoT Expert Swift Labs to Expand Connected Worker Portfolio

Dr. Agrafiotis pointed out, “I’m thrilled and honored to be part of this supremely talented team that combines generative AI with leading-edge automation and wet-lab science to reprogram human biology and transform the discovery and development of protein therapeutics at a speed and scale never seen before in our industry.”

Dr. Agrafiotis has co-authored more than 100 peer-reviewed publications and book chapters, and he holds 18 U.S.-issued patents. In 2012 he was elected Fellow of the Royal Society of Chemistry for his contributions to chemical and pharmaceutical research, and in 2016 he was named one of Computerworld’s Premier 100 Technology Leaders for his technology leadership and innovative approaches to business challenges.

Dr. Agrafiotis received a bachelor’s degree in chemistry from the University of Patras in 1985 and a doctorate degree in theoretical organic chemistry from Imperial College London in 1988. He held postdoctoral fellowships at the University of California, Berkeley and Harvard, where he worked with Nobel laureate EJ Corey.

Recommended AI News: Emerge Partners With TRIPP to Pioneer Tactile Meditation and Human Connection Within the Metaverse

[To share your insights with us, please write to sghosh@martechseries.com]